A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bioequivalence of a New Tapentadol Extended-Release (TRF) 100-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 100-mg Tablet Under Fasted Conditions in Healthy Subjects
Latest Information Update: 04 Jan 2014
At a glance
- Drugs Tapentadol (Primary)
- Indications Cancer pain; Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 04 Jan 2014 New trial record